{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:56:32Z","timestamp":1785527792037,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009337","name":"Saitama Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04931-8","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:53:17Z","timestamp":1785214397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a simplified population pharmacokinetic\u2013pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9926-557X","authenticated-orcid":false,"given":"Yoshinori","family":"Makino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-5690","authenticated-orcid":false,"given":"Reiko","family":"Makihara\u2013Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Sakiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-493X","authenticated-orcid":false,"given":"Maki","family":"Todo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-2568","authenticated-orcid":false,"given":"Masataka","family":"Hirasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0798-1396","authenticated-orcid":false,"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"4931_CR1","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713\u20134721. https:\/\/doi.org\/10.1200\/JCO.2002.02.140","journal-title":"J Clin Oncol"},{"key":"4931_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10637-010-9603-3","volume":"30","author":"AL Quartino","year":"2012","unstructured":"Quartino AL, Friberg LE, Karlsson MO (2012) A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 30:833\u2013845. https:\/\/doi.org\/10.1007\/s10637-010-9603-3","journal-title":"Invest New Drugs"},{"key":"4931_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","volume":"10","author":"DI Jodrell","year":"1992","unstructured":"Jodrell DI, Egorin MJ, Canetta RM et al (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520\u2013528. https:\/\/doi.org\/10.1200\/JCO.1992.10.4.520","journal-title":"J Clin Oncol"},{"key":"4931_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","volume":"26","author":"E Gamelin","year":"2008","unstructured":"Gamelin E, Delva R, Jacob J et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099\u20132105. https:\/\/doi.org\/10.1200\/JCO.2007.13.3934","journal-title":"J Clin Oncol"},{"key":"4931_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.1124","volume":"105","author":"JH Beumer","year":"2019","unstructured":"Beumer JH, Chu E, Allegra C et al (2019) Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther 105:598\u2013613. https:\/\/doi.org\/10.1002\/cpt.1124","journal-title":"Clin Pharmacol Ther"},{"key":"4931_CR6","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","volume":"89","author":"JT Slattery","year":"1997","unstructured":"Slattery JT, Clift RA, Buckner CD et al (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055\u20133060. https:\/\/doi.org\/10.1182\/blood.V89.8.3055","journal-title":"Blood"},{"key":"4931_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Thall PF, Madden T et al (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transpl 8:477\u2013485. https:\/\/doi.org\/10.1053\/bbmt.2002.v8.pm12374452","journal-title":"Biol Blood Marrow Transpl"},{"key":"4931_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","volume":"19","author":"AR Rezvani","year":"2013","unstructured":"Rezvani AR, McCune JS, Storer BE et al (2013) Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transpl 19:1033\u20131039. https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"4931_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1056\/NEJM198602203140803","volume":"314","author":"WE Evans","year":"1986","unstructured":"Evans WE, Crom WR, Abromowitch M et al (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314:471\u2013477. https:\/\/doi.org\/10.1056\/NEJM198602203140803","journal-title":"N Engl J Med"},{"key":"4931_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1056\/NEJM199802193380803","volume":"338","author":"WE Evans","year":"1998","unstructured":"Evans WE, Relling MV, Rodman JH et al (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499\u2013505. https:\/\/doi.org\/10.1056\/NEJM199802193380803","journal-title":"N Engl J Med"},{"key":"4931_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdw290","volume":"27","author":"M Joerger","year":"2016","unstructured":"Joerger M, von Pawel J, Kraff S et al (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 27:1895\u20131902. https:\/\/doi.org\/10.1093\/annonc\/mdw290","journal-title":"Ann Oncol"},{"key":"4931_CR12","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/bcp.13982","volume":"85","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhou F, Qi H et al (2019) Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol 85:2292\u20132301. https:\/\/doi.org\/10.1111\/bcp.13982","journal-title":"Br J Clin Pharmacol"},{"key":"4931_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"16","author":"R Bruno","year":"1998","unstructured":"Bruno R, Hille D, Riva A et al (1998) Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187\u2013196. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.187","journal-title":"J Clin Oncol"},{"key":"4931_CR14","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ejca.2003.12.026","volume":"40","author":"MA Rudek","year":"2004","unstructured":"Rudek MA, Sparreboom A, Garrett-Mayer ES et al (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40:1170\u20131178. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.026","journal-title":"Eur J Cancer"},{"key":"4931_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/1078-0432.CCR-10-1636","volume":"17","author":"FK Engels","year":"2011","unstructured":"Engels FK, Loos WJ, van der Bol JM et al (2011) Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 17:353\u2013362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1636","journal-title":"Clin Cancer Res"},{"key":"4931_CR16","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2014.55.2307","volume":"32","author":"F Innocenti","year":"2014","unstructured":"Innocenti F, Schilsky RL, Ram\u00edrez J et al (2014) Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 32:2328\u20132334. https:\/\/doi.org\/10.1200\/JCO.2014.55.2307","journal-title":"J Clin Oncol"},{"key":"4931_CR17","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1111\/cas.14194","volume":"110","author":"Y Makino","year":"2019","unstructured":"Makino Y, Makihara-Ando R, Ogawa T et al (2019) Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer. Cancer Sci 110:3573\u20133583. https:\/\/doi.org\/10.1111\/cas.14194","journal-title":"Cancer Sci"},{"key":"4931_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C et al (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6:669\u2013677. https:\/\/doi.org\/10.1016\/S1470-2045(05)70255-2","journal-title":"Lancet Oncol"},{"key":"4931_CR19","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjc.6605348","volume":"101","author":"Y Kishida","year":"2009","unstructured":"Kishida Y, Kawahara M, Teramukai S et al (2009) Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 101:1537\u20131542. https:\/\/doi.org\/10.1038\/sj.bjc.6605348","journal-title":"Br J Cancer"},{"key":"4931_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4143\/crt.2017.255","volume":"50","author":"C Xu","year":"2018","unstructured":"Xu C, Yang SP, Zhang Y et al (2018) Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area. Cancer Res Treat 50:777\u2013790. https:\/\/doi.org\/10.4143\/crt.2017.255","journal-title":"Cancer Res Treat"},{"key":"4931_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4196\/kjpp.2012.16.2.97","volume":"16","author":"D Kang","year":"2012","unstructured":"Kang D, Bae KS, Houk BE, Savic RM, Karlsson MO (2012) Standard error of empirical Bayes estimate in NONMEM\u00ae VI. Korean J Physiol Pharmacol 16:97\u2013106. https:\/\/doi.org\/10.4196\/kjpp.2012.16.2.97","journal-title":"Korean J Physiol Pharmacol"},{"key":"4931_CR22","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/cancers17193262","volume":"17","author":"JF Monteiro","year":"2025","unstructured":"Monteiro JF, Fernandes A, Tato DG et al (2025) Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring. Cancers (Basel) 17:3262. https:\/\/doi.org\/10.3390\/cancers17193262","journal-title":"Cancers (Basel)"},{"key":"4931_CR23","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1111\/bcp.16188","volume":"90","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Tsujimoto A, Ide T et al (2024) Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer. Br J Clin Pharmacol 90:2920\u20132930. https:\/\/doi.org\/10.1111\/bcp.16188","journal-title":"Br J Clin Pharmacol"},{"key":"4931_CR24","doi-asserted-by":"publisher","first-page":"1463915","DOI":"10.3389\/fimmu.2024.1463915","volume":"15","author":"A Lef\u00e8vre","year":"2025","unstructured":"Lef\u00e8vre A, Parra-Guillen ZP, Troc\u00f3niz IF, Boetsch C, Frances N (2025) Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies. Front Immunol 15:1463915. https:\/\/doi.org\/10.3389\/fimmu.2024.1463915","journal-title":"Front Immunol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04931-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04931-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04931-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:14:05Z","timestamp":1785521645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04931-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4931"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04931-8","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"81"}}